Key among the findings which may account for the aberrant activation of the AR in prostate cancer was the discovery that, in addition to classical ligand-binding mechanisms, transcriptional activity of the AR is controlled through its direct binding to the RhoA effectors PRK1 and PRK2 [46]. This evidence concerns the gene PKN1 and prostate carcinoma.